$476.31
3.94 (-0.82%)
Last updated: Jul 15, 2026 04:30
Fundamentals Overview
Vertex Pharmaceuticals Incorporated is in the middle of its 52-week range with moderate valuation, trading relatively flat today.
Valuation moderate
Intrinsic value (DCF)
-15.7% downside vs price
Profitability
Risk (Beta)
0.29 — lower vol
Earnings & growth
BullzEye Analysis
Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Supporting (Buy):
Analyst grade: A- · Sentiment improving (5 upgrades)
Pressures (Sell):
DCF 15.7% downside vs price
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Overall rating: A-. Recent institutional grades: majority upgrades. Current institutional positions: Buy: 9, Hold: 4, Outperform: 9, Overweight: 6, Sector Perform: 1, Underperform: 1.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $401.40; current price is $476.31. That’s a -15.7% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | 28.14 |
| DCF value (model) | $401.40 (-15.7% vs price) |
| PEG (TTM) | 0.05 |
| P/B (TTM) | 6.25 |
| P/S (TTM) | 9.86 |
| P/FCF (TTM) | 32.58 |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 3.02 |
| Quick Ratio (TTM) | 2.57 |
| Cash Ratio (TTM) | 1.42 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | 35.4% |
| Gross margin (TTM) | 86.28% |
| Operating margin (TTM) | 38.97% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for VRTX.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| Baird | maintain | Underperform | Underperform | 2026-07-07 |
| RBC Capital | maintain | Outperform | Outperform | 2026-07-07 |
| Barclays | maintain | Overweight | Overweight | 2026-05-06 |
| Bernstein | maintain | Outperform | Outperform | 2026-05-05 |
| Canaccord Genuity | maintain | Hold | Hold | 2026-05-05 |
| Morgan Stanley | maintain | Overweight | Overweight | 2026-05-05 |
| RBC Capital | maintain | Outperform | Outperform | 2026-05-05 |
| Canaccord Genuity | maintain | Hold | Hold | 2026-04-30 |
| Morgan Stanley | maintain | Overweight | Overweight | 2026-04-10 |
| Maxim Group | upgrade | Hold | Buy | 2026-03-18 |
| Truist Securities | maintain | Buy | Buy | 2026-03-11 |
| Citigroup | maintain | Buy | Buy | 2026-03-10 |
| Morgan Stanley | maintain | Overweight | Overweight | 2026-03-10 |
| Oppenheimer | maintain | Outperform | Outperform | 2026-03-10 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2026-03-10 |
| B of A Securities | maintain | Buy | Buy | 2026-03-10 |
| Barclays | maintain | Overweight | Overweight | 2026-02-17 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2026-02-17 |
| Canaccord Genuity | maintain | Hold | Hold | 2026-02-17 |
| HC Wainwright& Co. | maintain | Buy | Buy | 2026-02-17 |
| Oppenheimer | upgrade | Perform | Outperform | 2026-02-13 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2026-02-13 |
| Stifel | maintain | Hold | Hold | 2026-02-13 |
| RBC Capital | maintain | Outperform | Outperform | 2026-02-13 |
| Scotiabank | maintain | Sector Perform | Sector Perform | 2026-02-13 |
| Barclays | upgrade | Equal Weight | Overweight | 2026-01-28 |
| UBS | maintain | Buy | Buy | 2026-01-26 |
| Evercore ISI Group | maintain | Outperform | Outperform | 2026-01-23 |
| RBC Capital | upgrade | Sector Perform | Outperform | 2026-01-22 |
| Bernstein | upgrade | Market Perform | Outperform | 2026-01-12 |